UroGen Pharma
URGN
URGN
139 hedge funds and large institutions have $460M invested in UroGen Pharma in 2025 Q1 according to their latest regulatory filings, with 20 funds opening new positions, 45 increasing their positions, 48 reducing their positions, and 18 closing their positions.
New
Increased
Maintained
Reduced
Closed
Holders
139
Holders Change
+1
Holders Change %
+0.72%
% of All Funds
1.89%
Holding in Top 10
6
Holding in Top 10 Change
+2
Holding in Top 10 Change %
+50%
% of All Funds
0.08%
New
20
Increased
45
Reduced
48
Closed
18
Calls
$1.71M
Puts
$542K
Net Calls
+$1.17M
Net Calls Change
+$496K
Top Buyers
| 1 |
RCM
RA Capital Management
Boston,
Massachusetts
|
+$35.5M |
| 2 |
UBS AM
Chicago,
Illinois
|
+$33M |
| 3 |
VPC
Vestal Point Capital
New York
|
+$5.78M |
| 4 |
JPMorgan Chase & Co
New York
|
+$3.87M |
| 5 |
Schroder Investment Management Group
London,
United Kingdom
|
+$3.4M |
Top Sellers
| 1 |
Adage Capital Partners
Boston,
Massachusetts
|
-$18.3M |
| 2 |
CAM
Cormorant Asset Management
Boston,
Massachusetts
|
-$3.2M |
| 3 |
CF
Cantor Fitzgerald
New York
|
-$2.93M |
| 4 |
Millennium Management
New York
|
-$2.46M |
| 5 |
OM
Opaleye Management
Boston,
Massachusetts
|
-$2.34M |
